ALRN News and Press, Aileron Therapeutics Inc. From 10/16/19

The first participant has completed the initial cycle of treatment in a 120-subject  Phase 1b/2 clinical trial evaluating Aileron Therapeutics' ( ALRN +5.5% ) ALRN-6924 as a myelopreservation agent in patients with p52 mutation-positive small cell lung cancer (SCLC) treated with the ...

Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. Management plans to expand its ongoing clinical myelopreservation trial to include two additi...

WATERTOWN, Mass., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the presentation of interim results from its ongoing Phase 2a clinical trial evaluatin...

WATERTOWN, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today announced that an abstract on interim Phase 2a data for the Company’s lead product c...

Quick Take Aprea Therapeutics ( APRE ) intends to raise $75 million in an IPO, according to an amended registration statement . The company is developing drug treatments for MDS and acute myeloid leukemia. APRE has achieved impressive Phase 2 trial results for its lead candidate and exp...

Quick Take Aprea Therapeutics ( APRE ) has filed to raise gross proceeds of up to $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. APRE is in Phase 3 trials for it...

WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Don Dougherty, its current Chief Financial Officer, will be leavin...

WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Manuel Aivado, MD, PhD, President & Chief Executive Officer, w...

The following slide deck was published by Aileron Therapeutics, Inc. in conjunction with this Read more ...

Aileron Therapeutics (NASDAQ: ALRN ): Q2 GAAP EPS of -$0.26 misses by $0.02 . More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...